Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma.

Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma. J Clin Oncol. 2018 06 10; 36(17):1658-1667.

View in: PubMed

subject areas

Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
Biological Products
Female
Herpesvirus 1, Human
Humans
Ipilimumab
Male
Melanoma
Middle Aged
Neoplasm Staging
Proto-Oncogene Proteins B-raf
Skin Neoplasms
Young Adult

authors with profiles

MERRICK I ROSS